Cargando…
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented. METHODS: Patients were randomly assigned (1...
Autores principales: | Harrington, Kevin J., Burtness, Barbara, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Lin, Jianxin, Gumuscu, Burak, Swaby, Ramona F., Rischin, Danny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902012/ https://www.ncbi.nlm.nih.gov/pubmed/36219809 http://dx.doi.org/10.1200/JCO.21.02508 |
Ejemplares similares
-
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
por: Burtness, Barbara, et al.
Publicado: (2022) -
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022) -
Translating KEYNOTE-048 into practice recommendations for head and neck cancer
por: Szturz, Petr, et al.
Publicado: (2020) -
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
por: Bratland, Åse, et al.
Publicado: (2023) -
Keynotes
Publicado: (2023)